Answers are grounded in this paper and cite their sources.
Background Breast carcinoma is a biologically heterogeneous malignancy in which morphology alone does not reliably predict clinical behavior. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), and the proliferation marker Ki-67 are routinely used to refine prognostic assessment and to guide systemic therapy. The present study aimed to describe the histopathological spectrum of breast carcinoma at a tertiary care center in western India and to document how immunohistochemical receptor expression is distributed across histological grades. Materials and methods This retrospective observational study examined 67 histopathologically confirmed breast carcinomas reported in the Department of Pathology, Dhiraj Hospital, Sumandeep Vidyapeeth (Deemed to be University), Vadodara, between May 2023 and May 2025. Histological typing followed the fifth edition of the World Health Organization classification, and grading followed the Nottingham modification of the Scarff-Bloom-Richardson system. ER and PR were scored by the Allred method, HER2/neu was interpreted using the American Society of Clinical Oncology/College of American Pathologists criteria, and the Ki-67 labelling index was recorded. Cases were then assigned to immunohistochemistry-based surrogate molecular subtypes. Only descriptive statistics were applied; no inferential or correlation testing was performed. Results Invasive breast carcinoma of no special type accounted for 56 (83.6%) of 67 tumors. The age band of 41-50 years was the largest, with 34 (50.7%) patients, and 38 (56.7%) tumors measured 2-5 cm. Axillary nodal metastasis was present in 45 (67.2%) cases. Grade 2 tumors predominated, numbering 34 (50.7%). ER was positive in 34 (50.7%) cases, PR in 27 (40.3%), and HER2/neu in 27 (40.3%); the Ki-67 index was 14% or higher in 50 (74.6%) tumors. Luminal A was the commonest surrogate subtype at 24 (35.8%) cases, followed by luminal B at 18 (26.9%), triple-negative at 14 (20.9%), and HER2-enriched at 11 (16.4%). Triple-negative tumors clustered in grade 3, where 11 (64.7%) of 17 grade 3 carcinomas were triple-negative, whereas luminal A, luminal B, and HER2-enriched tumors were encountered most often among grade 2 lesions. Conclusions The cohort displayed wide histopathological and immunophenotypic variation. Reporting histological grade alongside ER, PR, HER2/neu, and Ki-67 status yielded a more complete description of each tumor than morphology alone and supports individualized treatment planning. The findings are descriptive and hypothesis-generating, and require confirmation in larger cohorts with formal statistical analysis.
No takes yet. Share an insight, caveat, or question.
Shukla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: